159 related articles for article (PubMed ID: 36199799)
61. Treatment with eFT-508 increases chemosensitivity in breast cancer cells by modulating the tumor microenvironment.
Yang ZY; Jiang CW; Zhang WL; Sun G
J Transl Med; 2022 Jun; 20(1):276. PubMed ID: 35717238
[TBL] [Abstract][Full Text] [Related]
62. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
63. The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease.
Brockhoff G; Seitz S; Weber F; Zeman F; Klinkhammer-Schalke M; Ortmann O; Wege AK
Oncotarget; 2018 Jan; 9(5):6201-6212. PubMed ID: 29464065
[TBL] [Abstract][Full Text] [Related]
64. SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer.
Baek SH; Kim JH; Bae SJ; Ji JH; Lee Y; Jeong J; Cha YJ; Ahn SG
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804813
[TBL] [Abstract][Full Text] [Related]
65. Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study.
Noske A; Möbus V; Weber K; Schmatloch S; Weichert W; Köhne CH; Solbach C; Ingold Heppner B; Steiger K; Müller V; Fasching P; Karn T; van Mackelenbergh M; Marmé F; Schmitt WD; Schem C; Stickeler E; Loibl S; Denkert C
Eur J Cancer; 2019 Jun; 114():76-88. PubMed ID: 31075727
[TBL] [Abstract][Full Text] [Related]
66. (-)-Sativan Inhibits Tumor Development and Regulates miR-200c/PD-L1 in Triple Negative Breast Cancer Cells.
Peng F; Xiong L; Peng C
Front Pharmacol; 2020; 11():251. PubMed ID: 32231566
[TBL] [Abstract][Full Text] [Related]
67. WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer.
Castagnoli L; Cancila V; Cordoba-Romero SL; Faraci S; Talarico G; Belmonte B; Iorio MV; Milani M; Volpari T; Chiodoni C; Hidalgo-Miranda A; Tagliabue E; Tripodo C; Sangaletti S; Di Nicola M; Pupa SM
Oncogene; 2019 May; 38(21):4047-4060. PubMed ID: 30705400
[TBL] [Abstract][Full Text] [Related]
68. PD-L1 testing based on the SP142 antibody in metastatic triple-negative breast cancer: summary of an expert round-table discussion.
Peg V; López-García MÁ; Comerma L; Peiró G; García-Caballero T; López ÁC; Suárez-Gauthier A; Ruiz I; Rojo F
Future Oncol; 2021 Apr; 17(10):1209-1218. PubMed ID: 33289433
[TBL] [Abstract][Full Text] [Related]
69. GBP5 Repression Suppresses the Metastatic Potential and PD-L1 Expression in Triple-Negative Breast Cancer.
Cheng SW; Chen PC; Lin MH; Ger TR; Chiu HW; Lin YF
Biomedicines; 2021 Apr; 9(4):. PubMed ID: 33916322
[TBL] [Abstract][Full Text] [Related]
70. Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade.
Pilones KA; Hensler M; Daviaud C; Kraynak J; Fucikova J; Galluzzi L; Demaria S; Formenti SC
Oncoimmunology; 2020 Oct; 9(1):1830524. PubMed ID: 33150045
[TBL] [Abstract][Full Text] [Related]
71. Dual Effect of Combined Metformin and 2-Deoxy-D-Glucose Treatment on Mitochondrial Biogenesis and PD-L1 Expression in Triple-Negative Breast Cancer Cells.
Repas J; Zupin M; Vodlan M; Veranič P; Gole B; Potočnik U; Pavlin M
Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267651
[TBL] [Abstract][Full Text] [Related]
72. Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer.
Liang Y; Liu X; Li K; Li H
Chin J Cancer Res; 2022 Apr; 34(2):117-130. PubMed ID: 35685994
[TBL] [Abstract][Full Text] [Related]
73. Atezolizumab for the treatment of triple-negative breast cancer.
Heimes AS; Schmidt M
Expert Opin Investig Drugs; 2019 Jan; 28(1):1-5. PubMed ID: 30474425
[TBL] [Abstract][Full Text] [Related]
74. [Correlation analysis of PD-L1 expression and prognosis in triple-negative breast cancers].
Pan BJ; Xu C; Ping GQ; Song GX; Zhang WM; Wang C; Zhang ZH
Zhonghua Bing Li Xue Za Zhi; 2017 Dec; 46(12):822-826. PubMed ID: 29224274
[No Abstract] [Full Text] [Related]
75. Saccharide analog, 2-deoxy-d-glucose enhances 4-1BB-mediated antitumor immunity via PD-L1 deglycosylation.
Kim B; Sun R; Oh W; Kim AMJ; Schwarz JR; Lim SO
Mol Carcinog; 2020 Jul; 59(7):691-700. PubMed ID: 32115801
[TBL] [Abstract][Full Text] [Related]
76. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
77. Biomimetic black phosphorus quantum dots-based photothermal therapy combined with anti-PD-L1 treatment inhibits recurrence and metastasis in triple-negative breast cancer.
Zhao P; Xu Y; Ji W; Zhou S; Li L; Qiu L; Qian Z; Wang X; Zhang H
J Nanobiotechnology; 2021 Jun; 19(1):181. PubMed ID: 34120612
[TBL] [Abstract][Full Text] [Related]
78. CDK4/6 inhibitors and the pRB-E2F1 axis suppress PVR and PD-L1 expression in triple-negative breast cancer.
Shrestha M; Wang DY; Ben-David Y; Zacksenhaus E
Oncogenesis; 2023 May; 12(1):29. PubMed ID: 37230983
[TBL] [Abstract][Full Text] [Related]
79. The PD-L1 Expression Among Triple-Negative Breast Cancer Patients in Universitas Sumatera Utara Teaching Hospital, Indonesia.
Hermansyah D; Kurniawan D; Lesmana DK; Simamora YR; Paramita DA; Siregar ES
Acta Inform Med; 2022 Dec; 30(4):308-311. PubMed ID: 36467323
[TBL] [Abstract][Full Text] [Related]
80. Identification and validation of the cellular senescence-related molecular subtypes of triple negative breast cancer via integrating bulk and single-cell RNA sequencing data.
Ju G; Zeng K; Lu L; Diao H; Wang H; Li X; Zhou T
Am J Cancer Res; 2023; 13(2):569-588. PubMed ID: 36895975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
